Gender-dependent pharmacokinetics of topotecan in adult patients

Anti-Cancer Drugs

Volumn 11, Issue 9, 2000, Pages 673-680

  Loos, Walter J ^a   Gelderblom, Hans J ^a   Verweij, Jaap ^a   Brouwer, Eric ^a   De Jonge, Maja J A ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Blood distribution; Hematocrit; In vitro; Lactone; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; ARTICLE; BODY COMPOSITION; BODY SURFACE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HEMATOCRIT; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOXYLIC ACIDS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOCRIT; HUMANS; INFUSIONS, INTRAVENOUS; LACTONES; MALE; NEOPLASMS; SEX FACTORS; TOPOTECAN;

EID: 0033673398     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200010000-00001     Document Type: Article

References (22)

1. Clinical pharmacokinetics of topotecan
2. Oral topotecan: Bioavailability and effect of food coadministration
3. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan
4. A multicenter, randomized, phase II study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma
5. A multicenter randomized phase II study of oral topotecan versus iv topotecan for second line therapy in sensitive patients with small cell lung cancer
6. Gender effects in pharmacokinetics and pharmacodynamics
7. Phase I and pharmacologic study of oral topotecan and intravenous cisplatin: Sequence dependent hematological side-effects
8. Phase II and pharmacologic study of topotecan administered as a 21-days continuous infusion to patients with colorectal cancer
9. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy-acid) in human plasma and urine
10. Population pharmacokinetics of topotecan in children and adolescents
11. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan
12. O-Glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan
13. Phase I and pharmacologic study of topotecan in patients with impaired renal function
14. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
15. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function
16. Heterogeneity of common hematologic parameters among racial, and gender subgroups
17. Erythrocytes and the transport of drugs and endogenous compounds
18. Role of red blood cells in pharmacokinetics of chemotherapeutic agents
19. Topotecan in physiologic fluids: Depot of active drug in red blood cells
20. Hycamtin (product monograph)
21. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20-(S)-camptothecin in humans